Research Nester released a report titled “Direct-Acting Antiviral Medicines Market: Global Demand Analysis & Opportunity Outlook 2029” which delivers detailed overview of the global direct-acting antiviral medicines market in terms of market segmentation by drug class type, end-user and region.
Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.
The direct-acting antiviral medicines market is projected to grow with a moderate CAGR during the forecast period, i.e., 2021-2029 on account of the rising prevalence of liver cirrhosis and hepatocellular carcinoma and the increasing investment in the development of advanced therapies. According to the World Health Organization (WHO), nearly 71 million people are living with chronic hepatitis C virus infection. Of these, a large group of population developed cirrhosis or liver cancer. Additionally, in 2016, nearly 399,000 people died from hepatitis C.
Download Sample of This Strategic Report @ https://www.researchnester.com/sample-request-3005
The market is segmented by drug class type into NS3/4A protease inhibitors, NS5A polymerase inhibitors, NS5B polymerase inhibitors, and combination drugs. Among these segments, the combination drugs segment is anticipated to hold the largest share by the end of 2021 in the direct-acting antiviral medicines market as a result of being considered as an appropriate medicine for treatment of liver diseases in a large number of clinical trials. On the basis of end-user, the market is segmented into hospital pharmacies, retail pharmacies, and others.
On the basis of region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, out of which, the direct-acting antiviral medicines market in the Asia Pacific is projected to grow at the highest CAGR throughout the forecast period. Currently, the market in North America holds the largest share. This can be attributed to the presence of leading healthcare providers in the region, accompanied by high awareness about direct-acting antiviral medicines in the region.
Increasing Prevalence of Liver Cirrhosis and Hepatocellular Carcinoma and Growing Investment in the Development of Advanced Therapies to Drive Market Growth
According to the Global Burden of Disease Study, in 2017, liver cirrhosis caused more than 1.32 million deaths globally which constituted 2.4% of the total global deaths in 2017.
Request a Sample Copy of Concerned Market Report @ https://www.researchnester.com/sample-request-3005
Chronic alcohol use is one of the most predominant risk factors for liver cirrhosis. It has been observed that individuals who consume high quantities of alcohol on a regular basis possess a high risk of having liver cirrhosis. Additionally, the rising prevalence of chronic viral infections of the liver in recent years is also expected to boost the market growth in upcoming years. However, poor access to direct-acting antiviral medicines in low income regions and side effects of direct-acting antiviral medicines are some of the factors that are estimated to restrain market growth in the near future.
This report also provides the existing competitive scenario of some of the key players of the global direct-acting antiviral medicines market which includes company profiling of AbbVie, Inc. (NYSE: ABBV), Janssen Therapeutics, Bristol-Myers Squibb (NYSE: BMY), Merck & Co. (NYSE: MRK), Vertex Pharmaceuticals (NASDAQ: VRTX), Johnson & Johnson (NYSE: JNJ), Gilead Sciences, Inc. (NASDAQ: GILD), Natco Pharma (NSE: NATCOPHARM), and Dr. Reddy’s Laboratories (NSE: DRREDDY). The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global direct-acting antiviral medicines market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
Curious about this latest version of report? Obtain Report Details @ https://www.researchnester.com/reports/direct-acting-antiviral-medicines-market/3005
About Research Nester
Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment, etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.
U.S. Phone: [+1 646 586 9123]
U.K. Phone: [+44 203 608 591]